Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity
- First Online:
- Cite this article as:
- Zhou, B., Li, C., Qi, W. et al. Diabetologia (2012) 55: 2032. doi:10.1007/s00125-012-2539-8
- 2.3k Views
Sirtuin-1 (SIRT1) is a potential therapeutic target to combat insulin resistance and type 2 diabetes. This study aims to identify a microRNA (miRNA) targeting SIRT1 to regulate hepatic insulin sensitivity.
Luciferase assay combined with mutation and immunoblotting was used to screen and verify the bioinformatically predicted miRNAs. miRNA and mRNA levels were measured by real-time PCR. Insulin signalling was detected by immunoblotting and glycogen synthesis. Involvement of SIRT1 was studied with adenovirus, inhibitor and SIRT1-deficient hepatocytes. The role of miR-181a in vivo was explored with adenovirus and locked nucleic acid antisense oligonucleotides.
miR-181a targets the 3′ untranslated region (3′UTR) of Sirt1 mRNA through a miR-181a binding site, and downregulates SIRT1 protein abundance at the translational level. miR-181a is increased in insulin-resistant cultured hepatocytes and liver, and in the serum of diabetic patients. Overexpression of miR-181a decreases SIRT1 protein levels and activity, and causes insulin resistance in hepatic cells. Inhibition of miR-181a by antisense oligonucleotides increases SIRT1 protein levels and activity, and improves insulin sensitivity in hepatocytes. Ectopic expression of SIRT1 abrogates the effect of miR-181a on insulin sensitivity, and inhibition of SIRT1 activity or SIRT1 deficiency markedly attenuated the improvement in insulin sensitivity induced by antisense miR-181a. In addition, overexpression of miR-181a by adenovirus impairs hepatic insulin signalling, and intraperitoneal injection of locked nucleic acid antisense oligonucleotides for miR-181a improves glucose homeostasis in diet-induced obesity mice.
miR-181a regulates SIRT1 and improves hepatic insulin sensitivity. Inhibition of miR-181a might be a potential new strategy for treating insulin resistance and type 2 diabetes.
KeywordsHepatocytesInsulin resistanceLocked nucleic acidMicroRNA
3′ Untranslated region
Glycogen synthase kinase 3β
Locked nucleic acid
Small interfering RNA
SH2 domain-containing protein tyrosine phosphatase 2
In recent years, type 2 diabetes mellitus has become a common chronic disease worldwide, a critical factor contributing to the pathogenesis of type 2 diabetes being insulin resistance [1, 2]. Sirtuin-1 (SIRT1), an NAD-dependent protein deacetylase, has been shown as a potential therapeutic target to combat insulin resistance and type 2 diabetes [3–5].
It has been reported that SIRT1 is a positive regulator of insulin signalling in skeletal muscle cells, adipocytes and hepatocytes [6–8]. Adenovirus-mediated overexpression of SIRT1 in the liver of insulin-resistant mice attenuates hepatic steatosis and ameliorates systemic insulin resistance . Moderate transgenic overexpression of Sirt1 in db/db and high-fat diet-fed mice improves glucose tolerance and insulin sensitivity [10, 11]. Aged mice orally administered resveratrol, which can enhance SIRT1 activity, display increased insulin sensitivity and survival . Resveratrol and its structural analogues, especially SRT1720, also protect mice against high-fat diet-induced obesity (DIO) and insulin resistance [13–15]. Further studies focused on the regulators of SIRT1 might provide potential new therapeutic approaches to combat insulin resistance and type 2 diabetes.
MicroRNAs (miRNAs) have been associated with many diseases, including type 2 diabetes [16, 17]. miR-278 mediates energy balance by regulating insulin responsiveness in Drosophila, and miR-278 mutants are insulin resistant . Aberrant expression of miRNAs has been observed in the insulin-target tissues of rat and mouse models of type 2 diabetes [19–21]. In adipocytes, miR-320 induces insulin resistance by inhibiting the insulin–phosphoinositide 3-kinase (PI3K) signalling pathway . miR-29, which has been found to be elevated in the skeletal muscle of diabetic rats and the liver of db/db mice, negatively regulates insulin signalling via inhibiting the p85α subunit of PI3K [23, 24]. In muscle cells, miR-7 downregulates IRS-1 levels as well as inhibiting insulin-stimulated Akt phosphorylation and glucose uptake . However, the role of miRNAs in regulating hepatic insulin sensitivity is still largely unknown.
In the present work, we sought to identify a miRNA targeting Sirt1 to regulate hepatic insulin sensitivity in vitro and in vivo, and to provide a potential approach for combating hepatic insulin resistance and type 2 diabetes.
Human, mouse and rat Sirt1 3′ untranslated region (3′UTR) sequences were retrieved from the Entrez Nucleotide database (http://www.ncbi.nlm.nih.gov/nuccore). The potential miRNA targets within the conserved regions in 3′UTR of Sirt1 were predicted by miRBase (www.mirbase.org/), TargetScan (www.targetscan.org/), PicTar (http://pictar.mdc-berlin.de/) and miRanda (www.microrna.org/microrna/home.do). Sirt1 3′UTR sequences from human, chimpanzee, dog, rat, mouse, chicken and pufferfish were aligned with each other and with the miR-181a seed region using PicTar.
Cell culture and treatments
HEK293T and HepG2 cells were maintained in DMEM with 10% FBS. Primary cultured mouse hepatocytes were prepared from 9-week-old C57BL/6 mice or the mice with the indicated genotypes by the collagenase perfusion method as described previously , and cultured in DMEM with 10% FBS.
For transfection, HEK293T, HepG2 cells or primary cultured mouse hepatocytes in 12-well plates were transfected with the indicated plasmids (1.6 μg/well), miRNA mimics, antisense oligonucleotides or small interfering RNA (siRNA) at the indicated final concentrations in the culture medium using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After transfection for 72 h, cells were subsequently stimulated with or without 100 nmol/l insulin (Sigma, St Louis, MO, USA) for 15 min and harvested for immunoblotting. To induce insulin resistance, HepG2 cells or primary cultured mouse hepatocytes were transfected for 54 h and then treated with 18 mmol/l glucosamine for 18 h in DMEM with 5 mmol/l glucose, before being stimulated with or without insulin for immunoblotting or measurement of glycogen synthase activity and glycogen synthesis assay. For adenovirus infection, HepG2 cells were infected with the indicated adenovirus at a multiplicity of infection of 50 for 8 h before transfection. To inhibit the activity of SIRT1, HepG2 cells were treated with 10 mmol/l nicotinamide or 50 μmol/l Sirtinol (Sigma) for an additional 12 h after transfection with antisense miR-181a at the indicated concentrations for 60 h. For the experiment considering insulin-induced insulin resistance, HepG2 cells were treated with 100 nmol/l insulin for 24 h. To upregulate SIRT1 protein level, HepG2 cells were treated with 0.5 mmol/l AICAR (Sigma) for 48 h.
C2C12 myoblasts were maintained in DMEM with 10% FBS and differentiated in DMEM with 2% horse serum after reaching confluence. After 4 days, the C2C12 cells were differentiated into myotubes and transfected with miR-181a mimics for 72 h at the indicated concentrations.
RNA isolation and real-time PCR
Total RNA was prepared using TRIzol reagent (Invitrogen). To measure mRNA levels, total RNA was reverse-transcribed and quantified by real-time PCR using Power SYBR Green (Applied Biosystems, Foster City, CA, USA). The primer sequences are shown in ESM Table 1. miR-181a was reverse-transcribed using a miR-181a-specific stem-loop primer (Applied Biosystems), and subsequently measured by real-time PCR using miR-181a-specific Taqman probes (Applied Biosystems). U6 (also known as Rnu6) was similarly measured and used for normalisation of miR-181a expression.
miRNA mimics, miRNA antisense oligonucleotides, siRNA and locked nucleic acid antisense oligonucleotides
miRNA-181a duplex mimics and 2′-O-methylated single-stranded miR-181a antisense oligonucleotides (anti-181a) were obtained from GenePharma (Shanghai, China). Irrelevant miRNA duplex mimics for Caenorhabditis elegans cel-miR-239b or 2′-O-methylated single-stranded cel-miR-239b antisense oligonucleotides were co-transfected as a mock control to equalise the total amount of miRNA or antisense oligonucleotides, respectively, for each transfection as described previously . SIRT1 and its control siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Locked nucleic acid (LNA) antisense oligonucleotides specific for miR-181a (LNA-anti-181a) and mismatched LNA oligonucleotides (LNA-control) were obtained from Exiqon (Vedbaek, Denmark).
HEK293T cells in a 24-well plate were co-transfected with pSIF-GFP or the indicated plasmids expressing miRNA precursors (0.8 μg/well), pRL-Sirt1-3′UTR (pRL-TK vector containing Sirt1 3′UTR) or pRL-Sirt1-3′UTRm (pRL-TK vector containing mutant Sirt1 3′UTR) (0.1 μg/well) and pSV40-β-gal (Promega, Madison, WI, USA) (0.1 μg/well) using Lipofectamine 2000. HepG2 cells in a 24-well plate were co-transfected with the indicated miRNA mimics, pRL-Sirt1-3′UTR (0.1 μg/well) and pSV40-β-gal (0.1 μg/well) using Lipofectamine 2000. After transfection for 72 h, cells were harvested for luciferase assay as previously described .
Immunoblotting was performed with antibodies against SIRT1 (Millipore, Billerica, MA, USA), α-tubulin (Sigma), GAPDH (Millipore), insulin receptor (INSR), Tyr1150/1151-phosphorylated INSR, Akt, Ser473-phosphorylated Akt, glycogen synthase kinase-3β (GSK3β), Ser9-phosphorylated GSK3β, SH2 domain-containing protein tyrosine phosphatase 2 (SHP2), acetyl-p53(K382), p53, acetyl-histone H3(K9), histone H3 (Cell Signaling, Beverly, MA, USA), G6Pase (Santa Cruz Biotechnology) and phosphoenolpyruvate carboxykinase (Novus, Littleton, CO, USA). Protein quantification was analysed by Quantity One software (Bio-Rad, Hercules, CA, USA), and normalised to α-tubulin or GAPDH.
Measurement of SIRT1 activity
SIRT1 deacetylase activity was determined using a SIRT1 Fluorimetric Activity Assay Kit (Biomol International, New York, NY, USA). Nuclear extracts from HepG2 cells were used for measuring SIRT1 deacetylase activity. Liver samples from mice fed chow or high-fat diet were lysed by radioimmunoprecipitation assay buffer, and then SIRT1 was immunoprecipitated to detect its deacetylase activity.
Details of the NAD assay are shown in the ESM Methods.
The fasting plasma of age-matched male control and diabetic participants was collected at the Centre Hospital of Xuhui District, Shanghai. Patients with fasting plasma glucose >7.0 mmol/l were considered to have diabetes, as previously described . Written informed consent was obtained from each participant, and the study was approved by the Institutional Review Board of the Institute for Nutritional Sciences. Serum RNA was isolated using TRIzol LS reagent (Invitrogen).
Measurement of glycogen synthase activity and glycogen synthesis assay
Glycogen synthase activity was determined using a modified method as previously described . HepG2 cells were treated with or without 100 nmol/l insulin for 10 min and harvested for glycogen synthase activity assay using uridine diphosphate-[3H]glucose (GE Healthcare, Piscataway, NJ, USA). Glycogen synthesis was determined as previously described . After transfection with the indicated miRNA mimics or antisense oligonucleotides at the indicated final concentrations for 72 h, HepG2 cells were processed with or without 100 nmol/l insulin and 3.7 × 104 Bq/ml [3H]glucose (Amersham, Van Nuys, CA, USA) in DMEM with 5 mmol/l glucose for 3 h, and then harvested for glycogen synthesis assay.
Generation of recombinant adenoviruses
To construct adenoviruses for overexpression of GFP, human SIRT1 or mouse miR-181a, complementary DNAs encoding mouse pre-miR-181a, human SIRT1 and GFP were inserted into pShuttle-CMV vector (Stratagene), and then subcloned into pAdEasy-1 adenoviral backbone vector (Stratagene). Recombinant adenoviruses were then generated following the manufacturer's protocol. Briefly, the adenoviral constructs were linearised with the restriction enzyme PacI and transfected into HEK293A cells using Lipofectamine 2000. After several rounds of propagation, the recombinant adenoviruses were purified by CsCl gradient centrifugation.
Details of the animal experiments are given in the ESM Methods.
Data are expressed as means±SD of at least three independent experiments. Statistical significance was assessed by Student’s t test except where indicated. Relationships between variables were determined by the Pearson correlation coefficient test. Differences were considered statistically significant at p < 0.05.
miR-181a targets Sirt1 3′UTR through an miR-181a binding site
To explore whether miR-181a directly targets Sirt1 3′UTR, we analysed the Sirt1 3′UTRs in human, chimpanzee, dog, rat, mouse, chicken and pufferfish by PicTar, and found that the potential binding site for miR-181a within Sirt1 3′UTRs is highly conserved from chicken to human (Fig. 1b). To test whether miR-181a represses the activity of Sirt1 3′UTR through this conserved site, we generated a reporter with a deletion of this site (Fig. 1c, upper panel). As expected, overexpression of miR-181a had no effect on the mutant reporter (Fig. 1c, bottom panel). To further confirm whether miR-181 targets Sirt1 3′UTR, a plasmid expressing mutant miR-181a with two mismatched bases in the seed region was constructed (Fig. 1d, upper panel). We found that the mutant miR-181a had no effect on the activity of Sirt1 3′UTR (Fig. 1d, bottom panel). These data demonstrate that miR-181a targets Sirt1 3′UTR through its binding site within Sirt1 3′UTR.
miR-181a decreases SIRT1 protein abundance at the translational level
miR-181a increases under insulin-resistant conditions
A similar increase in miR-181a was observed in the livers of db/db mice, a model of type 2 diabetes, where SIRT1 protein levels were decreased (Fig. 3h,i). In addition, miR-181a was also upregulated in the liver of mice fed with a high-fat diet, the content and activity of SIRT1 being decreased, which was further confirmed by the increased acetylation of p53 and histone H3 (Fig. 3j–l). Furthermore, miR-181a was significantly increased in the serum of patients with type 2 diabetes (Fig. 3m).
These results demonstrate that miR-181a increases under conditions of insulin resistance and may be associated with insulin resistance.
Overexpression of miR-181a represses SIRT1 and insulin sensitivity in hepatocytes
Inhibition of endogenous miR-181a increases SIRT1 and insulin sensitivity in hepatocytes under glucosamine-induced insulin-resistant conditions
SIRT1 is involved in the regulation of hepatic insulin sensitivity mediated by miR-181a
miR-181a regulates insulin sensitivity and glucose homeostasis in vivo
We then detected whether inhibition of endogenous miR-181a could improve insulin sensitivity in vivo. After intraperitoneal injection of LNA antisense oligonucleotides for miR-181a (LNA-anti-181a), miR-181a levels in the liver of DIO mice were markedly reduced (Fig. 7h). Moreover, inhibition of miR-181a by LNA-anti-181a significantly increased SIRT1 protein levels and the insulin-induced phosphorylation of INSR, Akt and GsSK3β in both the liver and muscle of DIO mice (Fig. 7e,f, ESM Fig. 5a). Meanwhile, hepatic protein and mRNA levels of Pepck and G6pase were both significantly decreased in the LNA-anti-181a-treated DIO mice (Fig. 7g,h). In addition, the hepatic mRNA levels of Acc1, Pparγ and Ptp1b were significantly decreased in the LNA-anti-181a-treated DIO mice (Fig. 7h). In the muscle of LNA-anti-181a-treated DIO mice, mRNA levels of Foxo1, Glut4 and Pgc1α were increased (ESM Fig. 5b). The alteration in these genes is consistent with the improved insulin signalling in liver and muscle (Fig. 7e,f, ESM Fig. 5a). In agreement with the improved insulin sensitivity in liver and muscle and the downregulation of key hepatic gluconeogenic enzyme genes induced by LNA-anti-181a, we found that LNA-anti-181a significantly downregulated 4-h fasting blood glucose levels and improved glucose tolerance in the DIO mice (Fig. 7i–k). Moreover, there was a positive correlation between the hepatic miR-181a levels and the fasting blood glucose, as well as the areas under the curve of glucose tolerance tests, in the DIO mice injected with LNA-anti-181a (Fig. 7l,m). Taken together, these data show that inhibition of miR-181a ameliorates DIO-induced hepatic insulin resistance and improves glucose homeostasis in DIO mice.
In this study, we identified SIRT1 as a direct target of miR-181a and demonstrated that miR-181a negatively regulates SIRT1 and hepatic insulin sensitivity. These results suggest that miR-181a might represent a potential therapeutic target for the treatment of insulin resistance and type 2 diabetes.
Recently, a study reported that miR-9, miR-135, miR-199b, miR-204, miR-181a and miR-181b reduce endogenous SIRT1 in mouse embryonic stem cells . In our study, we further demonstrate that miR-181a downregulates SIRT1 protein levels in hepatocytes and muscle cells. Moreover, our study also showed that miR-181a decreases SIRT1 protein levels in mouse liver. Previous studies have shown that SIRT1 can be regulated by multiple miRNAs, such as miR-9, miR-22, miR-34a, miR-132, miR-199a and miR-217 in some different biological processes [27, 30–32]. In our experiment, we similarly observed the inhibitory effect of these miRNAs. Moreover, we also discovered that miR-543 and miR-30a could significantly decrease the activity of Sirt1 3′UTR in HEK293T cells. miR-30a was found to reduce autophagic activity, which is positively regulated by SIRT1 [33, 34], suggesting that miR-30a may regulate autophagy by downregulating SIRT1. The distinct biological functions of these miRNAs targeting SIRT1 need to be further explored. In our study, although no obvious repressive effects of miR-22, miR-34a, miR-132 or miR-217 on Sirt1 3′UTR were observed in HEK293T cells, we did find their effects on Sirt1 3′UTR in HepG2 cells, suggesting that miRNAs may play different roles in different cells. Taken together, these findings suggest that SIRT1 is regulated by various miRNAs to function diversely in specific cells and tissues.
Many studies have investigated the function of miR-181a in tissues where it is highly expressed, such as thymus, brain and spleen [35, 36]. It has also been reported that miR-181a is a critical player in epithelial cell adhesion molecule (EpCAM)-positive hepatic cancer stem cells by targeting transcriptional regulators of differentiation . However, the biological function of miR-181a in liver is still poorly understood. Here we demonstrate for the first time that miR-181a is an important regulator in hepatic insulin sensitivity. Overexpression of miR-181a induces hepatic insulin resistance, whereas inhibition of endogenous miR-181a improves hepatic insulin sensitivity both in vitro and in vivo. Remarkably, inhibition of miR-181a by LNA-anti-181a improves glucose homeostasis in DIO mice. The efficacy and safety of LNA antisense oligonucleotides in inhibiting miRNA targets have been shown in mouse and non-human primate models [38, 39]. Several different LNA drugs are currently in clinical trials against cancer and infectious diseases . LNA-anti-181a might thus have potential therapeutic value for treating insulin resistance and type 2 diabetes. In addition, we found that miR-181a significantly increased in the serum of patients with type 2 diabetes, implying that serum miR-181a is a potential diagnostic marker, similar to other miRNAs described previously .
Consistent with our results, knockdown of SIRT1 impairs insulin signalling in HepG2 hepatoma cells . Liver-specific Sirt1 knockout mice display signs of hepatic insulin resistance, and exhibit significantly increased fasting glucose levels when fed with a high-fat diet . Hepatic SIRT1 deficiency in mice impairs mammalian target of rapamycin complex 2 (mTORC2)/Akt signalling and results in hyperglycaemia and insulin resistance . Furthermore, adenovirus-mediated overexpression of SIRT1 in the liver of ob/ob mice and of LDL receptor-deficient mice fed a high-fat high-sugar diet attenuates hepatic steatosis and ameliorates systemic insulin resistance . Similarly, our data show that inhibition of miR-181a by LNA-anti-181a is sufficient to improve hepatic insulin sensitivity accompanied by upregulation of SIRT1 protein levels in DIO mice.
Since a single vertebrate miRNA may target up to approximately 100–200 mRNAs , it is likely that some other miR-181a targets participate in the regulation of hepatic insulin sensitivity. SHP2, a tyrosine phosphatase, regulates insulin signalling positively and has been shown to be repressed by miR-181a in T cells [44, 45]. However, we found that protein levels of SHP2 were not changed in HepG2 cells or the liver of mice when miR-181a was overexpressed (data not shown). RNA-binding protein LIN-28 homologue A, another target of miR-181a, has also been reported as a positive regulator of insulin signalling [46, 47]. Foxo1 and Pgc1α were also predicted as miR-181a targets by PicTar or TargetScan. Whether these genes are involved in miR-181a-regulated hepatic insulin sensitivity needs to be investigated. In this study, we found that inhibition of SIRT1 activity or SIRT1 deficiency abrogated the positive effect of antisense miR-181a on insulin signalling, and overexpression of SIRT1 could sufficiently improve the insulin resistance induced by miR-181a. These data suggest that miR-181a regulates insulin sensitivity at least mainly through SIRT1. However, whether the effect of miR-181a on insulin sensitivity is SIRT1-dependent in vivo also needs to be studied.
SIRT1 has been reported as a positive regulator of insulin signalling by targeting protein tyrosine phosphatase 1B (PTP1B), AMPK, forkhead box O1 (FOXO1), peroxisome proliferator-activated receptor γ coactivator 1α (PGC1Α), and so on . Our in vivo experiments show that some glucose and lipid metabolism-related genes in liver or muscle, including Ptp1b, G6pase, Pepck, Acc1, Foxo1, Pgc1α and Glut4, are regulated by miR-181a. The alteration in these genes might be part of the underlying mechanisms by which miR-181a regulates insulin signalling through SIRT1. Besides miR-181a, miR-22 and miR-34a were also found to be elevated in the liver of diabetic db/db mice . Whether miR-22 and miR-34a can regulate insulin sensitivity through SIRT1 needs to be investigated.
In summary, our results indicate that miR-181a regulates hepatic insulin sensitivity and that SIRT1 is involved in this process. Inhibition of miR-181a is capable of improving hepatic insulin sensitivity and glucose homeostasis, which might provide a potential new therapeutic strategy for treating insulin resistance and type 2 diabetes.
The authors thank M. W. McBurney (Center for Cancer Therapeutics, Ottawa Hospital Research Institute) for providing the Sirt1+/− mice.
This work was supported by grants from National Natural Science Foundation of China (30825009, 30970619, 31030022 and 81021002), National Basic Research Program of China (973 Program, 2009CB918403 and 2007CB914501), Director Foundation of Institute for Nutritional Sciences (20090101), SA-SIBS Scholarship Program, China Postdoctoral Science Foundation (20100480641), National Science and Technology Support Program (2009BAI80B04), The Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-EW-R-09), the Postdoctoral Research Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (2011KIP511), Program of Shanghai Subject Chief Scientist (11XD1405800) and Shanghai Postdoctoral Scientific Program (11R21417400) and Shanghai Xuhui Central Hospital.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
This study was designed by BZ, CL and QWZ. The experiments were performed by BZ, CL, WQ, YZ, FZ, JXW, YNH, DMW, YL and TTY. QJ and MFL contributed to materials, methods and discussion. BZ, CL and QWZ analysed the data. QWZ supervised the project. CL, BZ and QWZ wrote the paper. All authors participated in data interpretation and revising the paper, and approved the final version of the manuscript.